叶下珠复方乙肝片联合干扰素治疗小儿慢性乙型肝炎30例

我们采用叶下珠复方乙肝片联合干扰素治疗慢性乙型肝炎患儿30例,并与单用干扰素治疗的30例比较,现将结果报告如下.     

复方止泻合剂治疗小儿秋季腹泻临床研究

20 0 0年 10月～ 2 0 0 2年 1月 ,笔者采用自拟复方止泻合剂治疗小儿秋季腹泻 ,并设对照组进行疗效观察。现将结果报告如下。1　资料与方法1.1　一般资料所有病例均为住院及门诊患儿 ,符合 1998年全国腹泻病防治研讨会制定的诊断标准。年龄 6个月～ 2岁 ,病程 <2 4小时。随机分     

扶正化痰合剂防治小儿哮喘的临床观察

目的 :观察扶正化痰合剂防治小儿哮喘的临床疗效。方法 :将 10 0例患儿随机分为扶正化痰合剂治疗组、酮替芬对照组各 5 0例 ,并观察治疗前后哮喘发作的次数及发作程度、血IgE、EOS的变化。结果 :在减少哮喘发作次数及减轻发作程度 ,降低血IgE及嗜酸性粒细胞水平等方面 ,治疗组均明显优于对照组 (P <0 0 5 )。结论 :扶正化痰合剂的临床疗效优于西药酮替芬 ;扶正化痰合剂可能是通过调节患儿血中IgE水平及嗜酸性粒细胞水平 ,从而改善患儿的病理变化 ,缓解哮喘发作。     

免疫脂质体抗癌药物靶向治疗血液肿瘤的研究进展

白血病是儿童发病率最高的恶性肿瘤,也是导致儿童死亡的主要原因.尽管联合化疗是当前治疗儿童血液恶性肿瘤的主要方法,可使儿童急性淋巴细胞白血病(ALL)的治愈率达80%,但还是有相当数量的白血病患儿难免复发死亡,尤其是急性髓系白血病(AML)的疗效远不如ALL.     

Targeting and internalization of sterically stabilized liposome modified with ZCH-4-2E8

Sterically stabilized liposome （SL） modified with 2E8 monoclonal antibody （2E8-SL） was prepared in order to evaluate its targeting ability and internalization efficiency against tumor cells with high expression of CD19.2E8 was coupled to the surface of SL using post-insertion technique. The shape of liposomes was observed under a transmission electronic microscope. The average size of liposomes was determined by using the Zetasizer instrument. The binding and internalization of 2E8-SL against tumor cells with higher expression of CD 19 were tested by flow cytometry and confocal microscopy. The mean diameter of 2E8-SL was 121.25 nm. 2E8-SL was stable after up to 24 days in various buffers. 2ES-SL showed specific binding to tumor cells with high expression of CD19, including B cells in peripheral blood mononuclear cells （PBMCs）. 2E8-SL could efficiently internalize into Nalm6 cells with CD19 high expression. It is suggested that 2E8-SL may serve as useful delivery carrier of anti-cancer drugs targeting to hematological malignant tumors with CD 19 high expression.     

免疫脂质体抗癌药物靶向治疗血液肿瘤的研究进展

白血病是儿童发病率最高的恶性肿瘤,也是导致儿童死亡的主要原因.尽管联合化疗是当前治疗儿童血液恶性肿瘤的主要方法,可使儿童急性淋巴细胞白血病(ALL)的治愈率达80%,但还是有相当数量的白血病患儿难免复发死亡,尤其是急性髓系白血病(AML)的疗效远不如ALL.     

免疫脂质体抗癌药物靶向治疗血液肿瘤的研究进展

白血病是儿童发病率最高的恶性肿瘤,也是导致儿童死亡的主要原因.尽管联合化疗是当前治疗儿童血液恶性肿瘤的主要方法,可使儿童急性淋巴细胞白血病(ALL)的治愈率达80%,但还是有相当数量的白血病患儿难免复发死亡,尤其是急性髓系白血病(AML)的疗效远不如ALL.     

免疫脂质体抗癌药物靶向治疗血液肿瘤的研究进展

白血病是儿童发病率最高的恶性肿瘤,也是导致儿童死亡的主要原因.尽管联合化疗是当前治疗儿童血液恶性肿瘤的主要方法,可使儿童急性淋巴细胞白血病(ALL)的治愈率达80%,但还是有相当数量的白血病患儿难免复发死亡,尤其是急性髓系白血病(AML)的疗效远不如ALL.     

小青龙汤治疗小儿寒哮的临床观察

目的探讨小青龙汤治疗小儿寒哮的疗效及作用机制.方法将60例寒哮的小儿随机分为两组,每组各30例,分别给予中药小青龙汤、西药氨茶碱治疗,观察治疗前后血IgE、EOS、IL 4、IFN γ等指标的变化.结果中药小青龙汤可显著降低血IgE和EOS水平,降低血清IL 4和增高IFN γ水平,其明显优于氨茶碱组(P<0.05).结论小青龙汤可显著改善患儿临床症状及细胞免疫紊乱状态,减轻和控制哮喘发作.     

Preparation and evaluation of norcantharidin-encapsulated liposomes modified with a novel CD19 monoclonal antibody 2E8

In this study, norcanthridin （NCTD）-encapsulated liposomes were modified with a novel murine anti-human CD19 monoclonal antibody 2E8 （2E8-NCTD-liposomes） and the targeting efficiency and specific cytotoxicity of 2E8-NCTD-liposomes to CD19^＋ leukemia cells were evaluated. BALB/c mice were injected with 2E8 hybridoma cells to obtain 2E8 monoclonal antibody （mAb）. NCTD-liposomes were prepared by using film dispersion method. 2E8 mAbs were linked to NCTD-liposomes using post-incorporation technology. Flow cytometry showed that the targeting efficiency of purified 2E8 mAbs on CD19＋ Nalm-6 cells was 99.93%. The purified 2E8 mAbs were conjugated with NCTD-liposomes to prepare 2E8-NCTD-liposomes whose targeting efficiency on CD19^＋ Nalm-6 was also 95.82%. The average size of 2E8-NCTD-liposomes was 118.32 nm in diameter. HPLC showed that the encapsulation efficiency of NCTD was 46.51%. When the molar ratio of 2E8/Mal-PEG2000-DSPE reached 1：50, we obtained the liposomes with 9 2E8 molecules per liposome. The targeting efficiency of 2E8-NCTD-liposomes on CD19^＋ leukemia cells was significantly higher than that on CD19-1eukemia cells. Similarly, the targeting efficiency of the immtmoliposomes was also higher than that of the NCTDAiposomes on CD 19^＋ leukemia cells. Those results were consistent with those observed by laser scanning confocal microscopy. 3-（4, 5-Dimethylthiazol-2-yl）-2,5-diphenyltetrazolium bromide （MTT） assay demonstrated that 2E8-NCTD-liposomes specifically killed Nalm-6 cells in a dose- and time-dependent manner. The viability of Nalm-6 cells treated by 2E8-NCTD-liposomes was significantly lower than that of Molt-3 cells and it was also significantly lower than that of Nahn-6 cells treated with the same concentration of NCTD-liposomes or free NCTD. We are led to concluded that 2E8 antigen can serve as a specific targeting molecule of B lineage hematopoietic malignancies for liposome targeting, and 2E8-NCTD-liposomes can be used as a new and effective means for the treatment of B lineage hematopoietic malignancies.